SGLT2i treatment at the beginning of real time exposure in a HFrEF population

被引：0
|
作者：
Vintila, V. [1 ]
Ciocanel, A. [2 ]
Stamate, E. [2 ]
Vintila, A. M. [3 ]
Vinereanu, D. [1 ]
机构：
[1] Univ Med & Pharm Carol Davila, Univ & Emergency Hosp Bucharest, Cardiol Dept, Bucharest, Romania
[2] Univ Emergency Hosp Bucharest, Cardiol Dept, Bucharest, Romania
[3] Univ Med & Pharm Carol Davila, Internal Med Dept, Coltea Clin Hosp, Bucharest, Romania
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2024年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：251 / 251
页数：1
相关论文
共 50 条
  • [41] SGLT2i: new perspectives in diabetes and kidney disease
    Ferrannini, Giulia
    Cosentino, Francesco
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (03) : E4 - E4
  • [42] Effects of SGLT2i on risk of hypovolaemia and UTI infections
    Reactions Weekly, 2024, 2036 (1) : 8 - 8
  • [43] Expanding the Use of SGLT2i in Diabetes Beyond Type 2
    Giaccari, Andrea
    DIABETES CARE, 2024, 47 (01) : 50 - 51
  • [44] Position of SGLT2i in prediabetes: A systematic review of literature
    Biswas, Kaushik
    Reddy, Vijaya Bhaskar
    Seshadri, Krishna
    Kapoor, Nitin
    Dharmalingam, Mala
    Anthuvan, Thamburaj
    JOURNAL OF DIABETOLOGY, 2025, 16 (02) : 102 - 114
  • [45] ARNI and SGLT2i: a promising association to be used with caution
    Andrea Herbst
    Francesco Orso
    Marta Migliorini
    Simona Virciglio
    Silvia Tognelli
    Viola Camartini
    Alessandra Pratesi
    Francesco Fattirolli
    Niccolò Marchionni
    Andrea Ungar
    Samuele Baldasseroni
    Journal of Geriatric Cardiology, 2020, 17 (11) : 728 - 732
  • [46] ARNI and SGLT2i: a promising association to be used with caution
    Andrea Herbst
    Francesco Orso
    Marta Migliorini
    Simona Virciglio
    Silvia Tognelli
    Viola Camartini
    Alessandra Pratesi
    Francesco Fattirolli
    Niccol Marchionni
    Andrea Ungar
    Samuele Baldasseroni
    Journal of Geriatric Cardiology, 2020, 17 (11) : 728 - 732
  • [47] SGLT2i: beyond the glucose-lowering effect
    Lihua Ni
    Cheng Yuan
    Guopeng Chen
    Changjiang Zhang
    Xiaoyan Wu
    Cardiovascular Diabetology, 19
  • [48] SGLT2i Prescribers Among CKD Patients: Trends in Real-World Data (RWD)
    Stavas, Joseph
    Butler, Emily L.
    Abdelhadi, Jenna
    Zhang, Tancy C.
    Rubens, Lexie
    Irwin, Debra E.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 573 - 573
  • [49] Class effects of SGLT2 inhibitors (SGLT2i) in the heart: SGLT2i inhibit NHE, reduce [Na+]c and activate vasorelaxation in isolated mouse cardiomyocytes/hearts
    Uthman, L.
    Baartscheer, A.
    Bleijlevens, B.
    Schumacher, C. A.
    Fiolet, J. W. T.
    Koeman, A.
    Hollmann, M. W.
    Weber, N. C.
    Coronel, R.
    Zuurbier, C. J.
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2017, 109 : 59 - 59
  • [50] SGLT2i treatment during AKI and its association with major adverse kidney events
    Alcantar-Vallin, Luz
    Zaragoza, Jose J.
    Diaz-Villavicencio, Bladimir
    Hernandez-Morales, Karla
    Camacho-Guerrero, Jahir R.
    Perez-Venegas, Miguel A.
    Carmona-Morales, Edgar J.
    Oseguera-Gonzalez, Alexa N.
    Murguia-Soto, Cesar
    Chavez-Alonso, Gael
    Arredondo-Dubois, Jose M.
    Orozco-Chan, Carlos E.
    Gomez-Fregoso, Juan A.
    Rodriguez-Garcia, Francisco G.
    Navarro-Blackaller, Guillermo
    Medina-Gonzalez, Ramon
    Gallardo-Gonzalez, Alejandro Martinez
    Abundis-Mora, Gabriela J.
    Vega-Vega, Olynka
    Garcia-Garcia, Guillermo
    Chavez-Iniguez, Jonathan S.
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345